Open AccessRecombinant BCG coexpressing Ag85B, ESAT‐6 and mouse‐IFN‐γ confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice
Author(s) -
Xu Ying,
Zhu Bingdong,
Wang Qingzhong,
Chen Jiazhen,
Qie Yaqing,
Wang Jiuling,
Wang Hongyan,
Wang Baolin,
Wang Honghai
Publication year - 2007
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.2007.00322.x
Subject(s) - esat 6 , immunogenicity , biology , mycobacterium tuberculosis , microbiology and biotechnology , antigen , recombinant dna , immune system , mycobacterium bovis , virology , mycobacterium , tuberculosis , fusion protein , antibody , tuberculosis vaccines , immunology , bacteria , medicine , gene , biochemistry , genetics , pathology
In this study, the protective efficacy of a novel recombinant bacille Calmette Géurin (BCG) strain (rBCG‐AEI) expressing fusion protein the antigen 85B (Ag85B)‐ the 6‐kDa early secreted antigen target (ESAT‐6)‐IFN‐γ against Mycobacterium tuberculosis H37Rv in mice was evaluated. The immunogenicity study showed that rBCG‐AEI could induce higher specific antibody titers and significantly increase cellular immune response than BCG, or rBCG‐A strain (expressing Ag85B), or rBCG‐AE strain (expressing fusion protein Ag85B‐ESAT‐6). The protective experiment demonstrated that rBCG‐AEI could confer similar or even better protective efficacy against M. tuberculosis infection compared with others in organ bacterial loads, lung histopathology and net weight gain or loss. The results suggested that rBCG‐AEI is a potential candidate for further study.